ACE and neoplasm: Comparative analysis of neoplasm cases where ARBs neoplasm served as reference were studied between ARBs versus ACE inhibitors revealed that neoplasm with ARBs (azilsartan ROR 1.522, 95% CI 0.892–2.598; candesartan ROR 1.00, 95% CI 0.8691–1.153; irbesartan ROR 1.630, 95% CI 1.398–1.900; Olmesartan ROR 1.388, 95% CI 1.226–1.571; losartan ROR 2.804, 95% CI 2.541–3.096; valsartan ROR 5.543 95% CI 5.146–5.97 and telmisartan ROR 1.72, 95% CI 1.476–2.014) was more frequent than with ACE inhibitor.